News und Analysen

Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food and Drug Administration (FDA) authorized marketing efforts

Sometimes it's hard to know which stocks to pick amid the dozens of options available on equity markets. But occasionally, some companies look so attractive that the decision isn't so difficult

Healthcare in the United States is big business: Experts believe the system could generate more than $6 trillion in annual spending by 2030. That's an opportunity for investors to find the key

The healthcare industry evolves rapidly. Those companies that stay relevant often do so by breaking new ground. So it's a good idea for investors looking for exciting healthcare stocks to look at

Is the stock market surge of 2023 running out of steam? That seems to be the case. The S&P 500 has retreated from the lofty levels of just a couple of months ago.

But there are some stocks that

There's no better time than October to invest in high-quality dividend stocks. That's because the new month offers a chance to get those dividend payments flowing sooner rather than later.

Three

Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market

Americans might not be as coronavirus-weary as some fear. Actually, these days they might be more coronavirus-wary. On the back of early take-up data for the latest COVID-19 vaccines that came out

Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer

Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).

The field of Alzheimer's disease (AD) has been where experimental drugs come to die in the past couple of decades. Many companies have tried and largely failed to develop new and effective therapies

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning.

What's

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private

Shares of medical device manufacturer AngioDynamics (NASDAQ: ANGO) jumped 5.3% through 12:05 p.m. ET on Monday ahead of its expected earnings release next month. This morning, investment bank H.C

UnitedHealth Group (NYSE: UNH) has seen its shares decline more than 6% so far this year. That may not seem like much of a drop, but for a company as steady as UnitedHealth, that represents a

Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far

Abbott Laboratories (NYSE: ABT) is seen as a solid safe-harbor stock because of the company's 135-year history, its diversified healthcare business, and its reliable dividend.

The company is known

There are many ways one can become richer, from trying to buy a winning lottery ticket to pouncing on some get-rich-quick scheme. Unfortunately, none of these methods is very reliable at all, unlike

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The decline

Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.

Three Motley Fool contributors identified bargain stocks to buy in a market that's

If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a